Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Why Regeneron Investors Shouldn't Fear Its Patent Cliff
Why Regeneron Investors Shouldn't Fear Its Patent Cliff
Why Regeneron Investors Shouldn't Fear Its Patent Cliff
Submitted by
admin
on May 26, 2022 - 10:08am
Source:
Motley Fool
News Tags:
Regeneron
patents
patent cliff
Eylea
Headline:
Why Regeneron Investors Shouldn't Fear Its Patent Cliff
snippet:
Patents on primary revenue driver EYLEA are set to expire soon.
Expanding indications for existing products will pick up the slack.
Oncology pipeline will drive future growth.
Do Not Allow Advertisers to Use My Personal information
